---
title: "UroGen Q2 FY26 net loss narrows to $14.4 million; revenue rises to $72.5 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294963066.md"
description: "UroGen Pharma reported Q2 FY26 revenue of $72.5 million, up from $24.2 million year-over-year, with a narrowed net loss of $14.4 million. ZUSDURI revenue surged 73% to $50.4 million, generating positive operating income. SG&A expenses rose due to commercial activities, while R&D costs decreased. The company holds $108 million in cash and raised full-year operating expense guidance to $260-$270 million. Management highlighted a new U.S. patent allowance for ZUSDURI and UGN-103 through 2044, with an NDA expected for UGN-103 in Q3 2026."
datetime: "2026-08-05T12:02:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294963066.md)
  - [en](https://longbridge.com/en/news/294963066.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294963066.md)
generator: "portal-rs"
---

# UroGen Q2 FY26 net loss narrows to $14.4 million; revenue rises to $72.5 million

-   UroGen posted Q2 2026 revenue of $72.5 million, up from $24.2 million a year earlier; net loss narrowed to $14.4 million. \* ZUSDURI revenue climbed 73% quarter-over-quarter to $50.4 million; operating income was $111,000. \* SG&A expenses rose to $48.4 million, reflecting ZUSDURI commercial activities; R&D expenses eased to $17.3 million. \* Cash, cash equivalents and marketable securities totaled $108 million; full-year operating expense guidance increased to $260 million-$270 million. \* Management cited a new U.S. patent allowance expected to protect ZUSDURI and UGN-103 into July 2044; UGN-103 remains on track for an NDA in Q3 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Urogen Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608050800PRIMZONEFULLFEED9803967) on August 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [URGN.US](https://longbridge.com/en/quote/URGN.US.md)

## Related News & Research

- [UroGen Pharma CMO Mark Schoenberg sells 60,677 common shares for $2.86 million](https://longbridge.com/en/news/296828951.md)
- [SoftwareOne attaches full H1 2026 report in correction to earlier release](https://longbridge.com/en/news/297010247.md)
- [Cemat publishes H1 2026 interim report](https://longbridge.com/en/news/297006906.md)
- [Ligand targets $150-$250 million in annual investments as royalty revenue tops $225 million in 2026 guidance](https://longbridge.com/en/news/297061481.md)
- [Ameriprise Financial declares Q3 2026 dividend of R$ 1.48 per unit](https://longbridge.com/en/news/297021432.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**